Latest Panitumumab Stories
MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc.
With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.
Large numbers of patients with advanced colon cancer should not get some of the most advanced drug treatments, a medical society study recommends. Patients whose tumors have certain mutations in a gene called KRAS should not receive drugs that include Erbitux, co-marketed in the United States by Eli Lilly & Co.
KRAS Biomarker Presents Potential to Personalize Colorectal Cancer Treatment Determining Who Can Benefit from Vectibix(R) THOUSAND OAKS, Calif., Dec.
QIAGEN N.V. (NASDAQ: QGEN) (FRANKFURT: QIA) today announced the launch of a new test to determine mutations of the K-ras gene. The K-ras gene is mutated in between 35 percent and 45 percent of metastatic colorectal cancer (CRC) patients.
Bristol-Myers Squibb and ImClone have presented five year data demonstrating an improved survival rate for head and neck cancer patients when receiving Erbitux and radiotherapy.
TrimGen Corporation, a U.S. molecular diagnostic company focused on developing advanced genetic tests, today announced the release of Mutector II(TM) KRAS kit.
MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc.
Clarient has launched its new offering, Kras, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer.
ALISO VIEJO, Calif., July 1 /PRNewswire-FirstCall/ -- Clarient, Inc.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.